Introduction {#s0005}
============

Neuronal nicotinic acetylcholine receptors (nAChRs) are involved in a wide variety of functions in the central nervous system (CNS) and are disrupted in several psychiatric and neurological disorders. The most abundant high-affinity nAChRs in the mammalian CNS contain the α4 and β2 subunits [@b0005; @b0010; @b0015] and this receptor subtype represents an important target for studies of functionally relevant protein--protein interactions. Heteromeric α4β2^∗^ nAChRs (where \* denotes other, potentially unidentified, subunits) bind nicotine with high affinity [@b0020; @b0025] and are targeted by pharmacotherapies for smoking cessation [@b0030], Alzheimer's disease [@b0035], Parkinson's disease [@b0040], mood disorders [@b0045] and attention deficit hyperactivity disorder (ADHD) [@b0050]. A better understanding of the nAChR signaling complex could lead to a better drug design to achieve desired therapeutic effects.

A number of studies have elucidated regulatory mechanisms that modulate nAChR function and cellular trafficking. The interaction of 14-3-3 adaptor proteins with α4 subunit affects the stoichiometry and agonist sensitivity of α4β2 nAChRs [@b0055; @b0060]. Interactions with the calcium-sensor protein VILIP-1 affect the agonist sensitivity and assembly of α4^∗^ nAChRs [@b0065]. Phosphorylation of α4 subunit by protein kinase A (PKA) affects association with 14-3-3 adaptor proteins and regulate α4β2 nAChR assembly [@b0060; @b0070]. Phosphorylation by protein kinase C (PKC) and dephosphorylation by the phosphatase calcineurin alter the transition of α4β2 nAChRs into and out of functionally desensitized states following prolonged exposure to agonists [@b0075; @b0080; @b0085]. Although these studies, and others, have identified protein--protein interactions with α4β2 nAChRs, our knowledge of the receptor interactome remains incomplete.

Mass spectrometry (MS)-based proteomic analysis allows simultaneous identification of multiple proteins present in varying quantities in complex mixtures. The ability of MS to obtain accurate peptide sequences, and subsequently identify proteins from these detected unique sequences using protein databases, has been a significant technological advance providing high-throughput accurate protein profiling (see [@b0090; @b0095] for review). A set of proteins that appear to be associated with β2^∗^ nAChRs were identified previously by analyzing proteins isolated from the mouse brain tissue using a β2-selective monoclonal antibody (mAb270) and MS with matrix-assisted laser desorption and tandem time-of-flight (MALDI--ToF-ToF) followed by comparison to complexes in β2 subunit null-mutant mice [@b0100]. This study demonstrated the utility of MS to detect nAChR-interacting proteins from the brain tissue. However, no quantitative methods have been employed to address specificity of the interaction between the identified proteins and the β2^∗^ nAChRs, as well as their partner subunits.

Stable isotopic labeling in cell culture (SILAC) has been used to identify highly specific protein--protein interactions. Selective protein was knocked down via siRNA in cultured cells grown in standard media, in comparison with cells grown in media supplemented with "heavy" amino acids [@b0105; @b0110]. However, this technique is limited by its capacity to compare only two samples, and stable isotopic labeling is not currently feasible for tissue homogenates. In contrast, label-free based quantitative MS is performed sequentially and thus introduces run-to-run variations in peptide elution, preventing accurate quantitation between sample sets. In order to facilitate identification of nAChR-interacting proteins with high confidence, we performed quantitative proteomic analysis using isobaric tags for relative and absolute quantitation (iTRAQ) [@b0115]. iTRAQ reduces variation by labeling multiple protein samples and mixing these samples together prior to liquid chromatography--tandem MS (LC--MS/MS) analysis, enabling identification and quantitation of multiple proteins from several samples concurrently [@b0120].

In this study, we combined the iTRAQ technique with the use of α4 and β2 nAChR subunit null-mutant mouse lines (these null-mutants express no functional α4β2 nAChRs [@b0020; @b0125] and heterozygotes express intermediate levels [@b0130]). A β2 subunit specific monoclonal antibody was used to isolate the receptors and quantify gene dose-dependent changes in the α4β2^∗^ nAChR interactome. The ability of iTRAQ to multiplex all six genotypes in a single LC--MS/MS experiment is essential for the quantitative identification and comparison of interacting proteins across genotypes. This integrated strategy recapitulates powerful cell-based techniques, but capitalizes on the ability of iTRAQ to label multiple *ex vivo* tissue samples. This technique identified a group of proteins that are associated linearly with mature nAChRs expressed in the mammalian brain and provided a platform for exploring functional relevance of this interactome.

Results {#s0010}
=======

Characterizing quantitative mAb295-M270 solid phase immunodepletion of β2^∗^ nAChRs from mouse brain {#s0015}
----------------------------------------------------------------------------------------------------

We first generated mAb295-coupled M270 Dynabeads using 0.5, 1, 2 or 5 μg of mAb295/mg of M270 beads in order to determine the optimal concentration of beads as well as the optimal ratio of bead suspension to brain extracts for quantitative immunoprecipitation of β2^∗^ nAChRs. Increasing volumes (0, 1.56, 3.125, 6.25, 12.5, 25, 50, 100 μl) of bead suspension from each concentration of mAb295 were used to capture β2^∗^ nAChRs labeled with 1 nM \[^3^H\]-epibatidine. Brain samples of three C57BL/6 mice were solubilized. After centrifugation, supernatants were pooled, and 100 μl aliquots were used in triplicate for each concentration of mAb295 across all eight bead volumes to measure the efficiency and extent of \[^3^H\]-epibatidine binding site capture. Depletion of \[^3^H\]-epibatidine binding from mouse brain extracts by immobilized mAb295 was saturable and nearly complete across all four concentrations of mAb295 tested ([Figure S1A](#s0110){ref-type="sec"}). The ½ maximal bead volume for nAChR capture decreased with increasing concentrations of mAb295 (*R*^2^ = 0.83; [Figure S1B](#s0110){ref-type="sec"}), but the calculated maximal binding site capture was not significantly different across the four mAb295-M270 bead ratios (*F*~(3,~ ~11)~ = 1.23, *P* = 0.36). This suggests that the amount of mAb295 coupled to the magnetic beads is more important for efficient capture of β2^∗^ nAChRs than the total available surface area of the beads themselves. Therefore, under the conditions outlined in this experiment, steric hindrance of protein complexes adhering to the nAChRs was not likely to affect the ability of the mAb295-M270 beads to trap solubilized β2^∗^ nAChRs and their associated protein complexes from brain extracts effectively. Calculated parameters for specific capture of \[^3^H\]-epibatidine binding sites by mAb295-M270 beads are presented in [Table S1](#s0110){ref-type="sec"}.

Immunopurification of β2^∗^ nAChRs from brain tissue of α4 or β2 subunit transgenic mice {#s0020}
----------------------------------------------------------------------------------------

Using optimal conditions (5 μg mAb295/mg M270 beads; bead volume 10% of total extracts), we extracted β2^∗^ nAChRs from mouse brain extracts prepared from wild type (WT), heterozygous (HET) and homozygous (KO) mice lacking either α4 or β2 nAChR subunit. There was a gene dose-dependent effect on the number of total \[^3^H\]-epibatidine binding sites in brain detergent extracts ([Table 1](#t0005){ref-type="table"}) across genotypes. There was no significant binding site capture from brains of α4 KO or β2 KO mice. No significant difference was detected in the percentage of binding sites captured from tissue samples of WT and HET α4 (79.6 ± 5.4 vs 83.1 ± 7.5%; *n* = 3, *P* = 0.72, *t*-test) or β2 (79.3 ± 0.9 vs 78.8 ± 1.3%; *n* = 3, *P* = 0.78, *t*-test), indicating that immobilized mAb295 performed similarly in all samples regardless of nAChR protein content.

Measurement of relative expression of nAChR subunit proteins by iTRAQ and LC--MS/MS {#s0025}
-----------------------------------------------------------------------------------

Quantitation of iTRAQ measured abundance is expressed as the log~2~ of the ratio of mean reporter ion peak areas (log~2~MRIPA) of all proteins present in all samples relative to the average WT abundance of the β2 nAChR subunit (the target of the IP). Since α4 and β2 nAChR subunit levels vary with gene dose, we evaluated their levels in each sample to judge the ability of iTRAQ to quantify proteins in immunocaptured eluates. Although \[^3^H\]-epibatidine binding sites varied with α4 and β2 genotypes, total protein eluted following immunoprecipitation (IP) did not differ significantly across genotypes (*F*~(5,~ ~17)~ = 2.52, *P* = 0.09). However, log~2~MRIPA ratio of β2 nAChR subunit was significantly affected by nAChR subunit knockout in a gene dose-dependent fashion (mean log~2~MRIPA ± SEM; α4 WT: 0.12 ± 0.17, HET: −0.31 ± 0.16, KO: −0.94 ± 0.23; *F*~(2,~ ~8)~ = 7.39, *P* = 0.024; one-way ANOVA. β2 WT: −0.19 ± 0.23, HET: −0.60 ± 0.31, KO: −1.53 ± 0.19; *F*~(2,~ ~8)~ = 8.35, *P* = 0.018; one-way ANOVA). However, although the log~2~MRIPA ratio for α4 subunit was significantly affected by α4 subunit knockout in a gene dose-dependent fashion (mean log~2~MRIPA ± SEM; WT: 0.09 ± 0.25, HET: −0.46 ± 0.39, KO: −1.44 ± 0.05; *F*~(2,~ ~8)~ = 9.34, *P* = 0.014; one-way ANOVA), such alteration was not obviously observed in β2 subunit knockout mice (WT: −0.21 ± 0.33, HET: −0.42 ± 0.23, KO: −1.40 ± 0.43; *F*~(2,~ ~8)~ = 3.27, *P* = 0.1; one-way ANOVA; [Figure 1](#f0005){ref-type="fig"}). Log~2~MRIPA was correlated positively with \[^3^H\]-epibatidine binding sites captured by immobilized mAb295 for both α4 (*R*^2^ = 0.80, *P *\< 0.0009) and β2 subunit (*R*^2^ = 0.65, *P *\< 0.0009), indicating that log~2~MRIPA ratio for each subunit is a reliable measure of the assembled nAChRs in each sample. The data for α4 and β2 WT, HET and KO mice appear as three distinct groupings along the regression line ([Figure 2](#f0010){ref-type="fig"}).

It should be noted that the log~2~MRIPA ratio measures the relative abundance of labeled peptides using a control sample as a reference. In fact, peptides that uniquely identify β2 and α4 nAChR subunits were detected in the subunit KO brain tissue, despite the lack of \[^3^H\]-epibatidine binding. These data are consistent with the fact that neither β2 nor α4 knockout completely abolishes the entire extracellular domain of the β2 nAChR subunit that is specifically recognized by mAb295 [@b0020; @b0125]. Thus, although these nAChR subunit knockouts completely eliminate nicotinic agonist binding sites and functional nAChRs, a small amount of a non-functional protein appears to be produced that is able to form some complexes with interacting proteins.

Defining and stratifying an α4β2^∗^ nAChR interactome by multiple linear regression following iTRAQ LC--MS/MS {#s0030}
-------------------------------------------------------------------------------------------------------------

We performed multiple linear regression on the positively identified proteins in the three biological replicates to identify highly specific interacting peptides whose relative abundance changes proportionally with the amount of quantitated nAChRs. Included proteins were identified by more than one significant and unique peptide (peptide expectation score \<1.7, corresponding to a confidence interval of 95%) in at least one biological replicate. There were 208 proteins identified by LC--MS/MS acquired, iTRAQ labeled peptides, with linear correlation coefficients ranging from +1 for β2 nAChR subunit to −0.847 for vesicle-associated membrane protein 2 (VAMP2) ([Table S2](#s0110){ref-type="sec"}).

Identification of significant α4β2^∗^ interacting proteins {#s0035}
----------------------------------------------------------

We did not fractionate tissue prior to processing, which maximized β2^∗^ nAChR content, but also introduced proteins from irrelevant cellular compartments that formed complexes with the immunopurified nAChRs. Some proteins appeared to be associated quite strongly (*r* \> 0.5 using Pearson's product moment correlation coefficient since the relationship between nAChR subunit gene dose and receptor expression is linear) with β2^∗^ nAChRs (such as certain histone isoforms), despite the fact that nAChRs would not be expected to localize to the nucleus or mitochondria. The UniProt Knowledgebase (UniProtKB) [@b0135] was therefore used to cull proteins from the list when the assigned cellular compartment did not correspond to sites of known nAChR localization. Exceptions were made in the case of two transcription factors: Pur-α, which has the capacity to translocate from the cytosol to the nucleus [@b0140], and thyroid hormone receptor-associated protein 3 (THRAP3), which we previously identified in an additional unpublished nAChR interactome study. Additional analysis focused only on 91 proteins in these compartments, with 62 identified as cytoplasmic, 26 associated with the plasma membrane and the remaining 3 proteins associated with the Golgi apparatus/endomembrane system ([Table 2](#t0010){ref-type="table"}). Of these, only 17 proteins (11 cytoplasmic and 6 associated with the plasma membrane) showed statistically significant correlation with levels of the β2 nAChR subunit ([Table 3](#t0015){ref-type="table"}). Classification of these 17 proteins with PANTHER Gene Ontology (GO) of molecular function [@b0145] revealed distinct biological activity profiles ([Table 3](#t0015){ref-type="table"}).

In the primary (unfiltered) dataset, distribution of correlation coefficients for β2 log~2~MRIPA was distinctly bimodal, with a major mode occurring between 0 and −0.5, and a minor mode occurring between 0.25 and 0.75 ([Figure 3](#f0015){ref-type="fig"}**A**). These data suggest that this dataset represents two sets of events: proteins that likely interacted with the antibody complex when it was not occupied by nAChRs (*r* \< 0) and proteins that interacted selectively with the immunoprecipitated nAChRs (*r* \> 0.25). In the secondary dataset, adjustment for cellular compartment eliminated the events with *r* \< 0 and resulted in a unimodal distribution approximately equivalent to the minor mode with *r* \> 0.25 ([Figure 3](#f0015){ref-type="fig"}**B**). These data suggest that eliminating the group of proteins that are not co-localized with the nAChRs in these cellular compartments also screens out the majority of proteins that interact non-specifically with the antibody complex. The tertiary dataset (selected for significant positive correlation with β2 nAChR subunit expression; *P *\< 0.05) was also unimodal, with the majority of the distribution centered between 0.5 and 0.75 ([Figure 3](#f0015){ref-type="fig"}**C**). Eliminating proteins based on cellular compartments favored identification of more positive correlations with β2 nAChR subunit abundance. Such result is consistent with the observation that calculated kurtosis for the frequency distribution increased from an estimate of −0.513 to 1.211 when moving from the primary to secondary dataset, an indication that the selected datasets deviated significantly from chance. Indeed, all three frequency distributions were significantly different from a normal distribution according to Shapiro--Wilk test (*P* = 0.006, 0.021 and 0.022 for primary, secondary and tertiary dataset, respectively), indicating that the samples were substantially enriched for a particular target protein and the associated proteins identified were largely non-random.

Discussion {#s0040}
==========

This study used quantitative protein identification with iTRAQ and LC--MS/MS to identify protein--protein interactions for α4β2 nAChRs. A highly specific monoclonal antibody was used to capture β2^∗^ nAChRs reliably and efficiently from detergent extracts of mouse brain homogenates, facilitating the identification of a set of putative nAChR-interacting proteins. Proteins of particular interest were identified, amounts of which tend to follow a linear trend with respect to the measured quantity of α4β2^∗^ nAChRs that are present in the samples from WT, HET and KO mice transgenic for the α4 or β2 subunit. The log~2~MRIPA ratios (transformed representation of average protein abundance measured by iTRAQ) of the individual α4 and β2 nAChR subunit proteins were significantly correlated with the measured \[^3^H\]-epibatidine binding sites, supporting the accuracy and reproducibility of iTRAQ-coupled LC--MS/MS. Previous studies have shown that expression of α4 nAChR subunits is largely dependent on that of β2 subunit; however, low levels of β2^∗^ nAChRs remain in the absence of α4 [@b0130; @b0150]. Additional α subunits (α2, α3 and α6) are expressed in the CNS and can form functional nAChRs together with β2 subunits [@b0155]. Although the non-α4 nAChRs are not sufficiently abundant to allow identification of these complexes from the whole brain lysate by iTRAQ. Our measurements of α4 and β2 nAChR subunit peptides across the six genotypes using iTRAQ are consistent with published studies on the effect of subunit null-mutation on mature β2^∗^ nAChR subtype expression. Importantly, our measures indicate that in the absence of a partner subunit, individual nAChR subunit monomers contributing to heteromeric α4β2^∗^ nAChRs are not apparent, and that multi-subunit complexes are required to prevent rapid degradation of free subunits.

nAChR peptides have been recognized previously by mAbs in knockout mouse tissue [@b0150]. The genomic DNA encoding the majority of the extracellular domain of the β2 nAChR subunit (recognized by mAb295) is not removed by exon deletion, through which the α4 and β2 nAChR subunit knockout mice were generated [@b0020; @b0125], so identification of low levels of α4 and β2 nAChR subunit peptides in their respective KO mice is not surprising. It is also possible that some of the peptides recovered in the α4 and β2 KO samples are incorrectly identified as a result of chimeric spectra in MS/MS that do not actually represent nAChR subunit peptides; however, chimeric spectra generally result in uncertainty of protein identification, rather than positive identification of peptides that are not actually present in the sample [@b0160].

It is possible that truncated nAChR subunit peptides in KO tissue cannot form binding sites but retain some features of nascent nAChR assembly intermediates, since measurable \[^3^H\]-epibatidine binding sites decreased in gene-dose-dependent fashion following nAChR subunit deletion, while the amount of total eluted protein following mAb295 affinity purification did not change. In addition, when comparing functions of proteins identified in the dataset adjusted for improper cellular compartment to those in the dataset adjusted for correlation with β2 nAChR subunit expression, proteins serving chaperone isomerase, and ER-Golgi transport functions are lost. Therefore, proteins captured from detergent extracts of KO brain homogenates that do not follow the regression trend likely represent proteins that are associated with incomplete/immature β2^∗^ nAChRs, while the more strongly and significantly correlated proteins potentially interact with mature receptors. Proteins negatively correlated with nAChR subunit levels may be involved in degradation and/or compartmentalization of non-functional nAChR proteins, or may bind to mAb295 and accumulate in the absence of bound nAChRs.

The use of iTRAQ coupled with α4 and β2 nAChR subunit transgenic mouse tissue provides a significant technical advance over previous proteomic methods used to identify specific nAChR-interacting proteins. Separating samples with difference in gel electrophoresis (DIGE) and eliminating bands/spots that appear in the KO control condition prior to LC--MS/MS pose the risk of missing significantly-associated proteins that are expressed in low abundance and may co-migrate with non-specifically captured proteins [@b0165]. Mulitplexing with iTRAQ and identifying as many proteins as possible in the post-IP eluent reduce the risk of missing proteins of interest due to preprocessing steps like DIGE, but increase the risk of identifying proteins that are not necessarily associated with assembled α4β2^∗^ nAChRs. Combining SILAC with siRNA-mediated knockdown reduces identification of false interacting proteins, which is not suited to tissue samples and is limited to a direct comparison of two samples [@b0110]. To address this issue, we took advantage of quantitation using iTRAQ to generate linear regression of the apparent abundance of each identified protein together with that of the β2 nAChR subunit across the six genotypes examined in each sample set, allowing us to identify a continuum of protein associations, ranging from highly positive to highly negative correlations.

Previously suggested nAChR-interacting proteins were lost from the dataset as our analysis became more stringent. Eight (out of 17 in total) of α4β2 nAChR-interacting proteins identified by MALDI--ToF-ToF [@b0100] are retained when identified proteins are restricted by cellular compartments, and 1 (out of 17) is identified when only proteins whose expression were significantly correlated with β2 nAChR subunit expression levels were considered, suggesting that these previous analyses may have suffered from missed identification and potentially false positive interactions. The current method, in contrast to MALDI--ToF-ToF [@b0100], identified a significant correlation between the relative abundance of α4 nAChR subunit and the abundance of its primary partner β2 (*r* = 0.858). It is important to note that proteins listed in a recent comprehensive review (2011) [@b0170] include those whose interactions are inferred from modulatory interactions (as with protein kinases and phosphatases which are known to phosphorylate or dephosphorylate the nAChRs). Such interactions are transient and may be cell-type specific. Therefore, future studies using enriched samples from a particular brain region and/or neuronal phenotype will be required to validate such associations.

Interpretation of interacting proteins that are not likely to interact in functionally relevant ways with target proteins is a caveat in current proteomic methods. This highlights the need to curate results of these analyses carefully and is part of the tradeoff for enhanced discovery and unbiased identification of novel interacting proteins. Examining the relative subcellular distribution of identified proteins in each of the lists generated by increasingly stringent criteria provided some interesting insights. Culling proteins by cellular compartment resulted in a dataset of 91 identified proteins in which 68% were cytoplasmic. Some Golgi/ER membrane resident proteins were also identified, indicating that the list of 91 interacting proteins likely includes proteins that interact with β2^∗^ nAChRs during assembly or maturation. The relative subcellular distribution of nAChRs in neurons *in vivo* is unknown, but cell surface expression of α4β2^∗^ nAChRs varies both by brain region and model organism [@b0175; @b0180]. The list of 17 proteins whose expression is correlated significantly with that of β2 nAChR subunit eliminates the Golgi/ER resident proteins, suggesting that this group represents proteins that largely interact with mature nAChRs present in the plasma membrane. Interactions with other plasma-membrane resident proteins are likely disrupted following solubilization. This is reflected in the list of 91 interacting proteins, where the majority (65%) are cytoplasmic proteins, indicating that in the mature state, the large cytoplasmic loop of each subunit that resides between transmembrane domains 3 and 4 represents the primary site for intracellular protein--protein interactions.

Establishing molecular function classifications with PANTHER pathway analysis [@b0145] reveals that the primary interactions of mature β2^∗^ nAChRs occur with structural proteins that are part of, and regulate the growth and assembly of, the cytoskeleton. These data are consistent with studies showing that β2^∗^ nAChRs are involved in production and maintenance of dendritic spines during development [@b0185]. Of particular interest are the cytoskeletal proteins that appear to play functional roles in the growth and reorganization of synaptic processes, such as actin-related protein 3 (Arp3) and F-actin capping protein subunit α2. Arp3 contributes directly to axon branching [@b0190] and is implicated in strain differences in hippocampal information processing [@b0195]. Activity-dependent accumulation of F-actin capping proteins occurs in dendritic spines [@b0200], supporting the idea that β2^∗^ nAChRs play a role in dynamic neuronal cytoarchitecture remodeling and providing a potential molecular mechanism for future evaluation.

Two isoforms of calcium/calmodulin-dependent protein kinase II (CaMKII), α and γ, were identified in the current experiment. CamKII is involved in nAChR recycling [@b0205] and α-kinase-anchoring protein (αKAP, a CaMKII anchoring protein) inhibits proteasomal degradation of muscle-type nAChRs [@b0210]. CaMKII is also a critical mediator of long-term potentiation (LTP) (see [@b0215] for review), a molecular mechanism underlying memory storage. CaMKIIα is specifically associated with the postsynaptic density in excitatory neurons (see [@b0220] for review) and previous studies have demonstrated that acute nicotine exposure in mice activates CaMKII in the spinal cord and brain, which requires activation of β2^∗^ nAChRs [@b0225; @b0230]. In addition, β2^∗^ nAChR-mediated activation of CaMKII is an essential component of the antinociceptive effects of nicotine [@b0235] and affective signs of nicotine withdrawal [@b0240]. Chronic nicotine exposure results in an increase in CaMKIIα expression and function in nucleus accumbens of mice and this effect is attenuated following administration of a β2 nAChR selective antagonist [@b0245]. Nicotine also influences several aspects of hippocampal-dependent learning [@b0250]. Identification here of a direct association between α4β2^∗^ nAChRs and CaMKIIα provides rationale for future studies of its role in hippocampal plasticity.

It should be noted that glial fibrillary acidic protein (GFAP) is one of the most highly correlated proteins identified in the curated list of proteins. Homomeric α7 nAChRs have been reported to be expressed on astrocytes [@b0255]. However evidence of α4β2 nAChR expression on non-neuronal CNS cells is lacking. Identification of GFAP in this study may imply that α4β2^∗^ nAChRs could participate in neuron--glia interactions.

In conclusion, we have identified a novel set of nAChR-interacting proteins that are consistent with known nAChR-mediated functions, as well as previously identified interactors such as spectrin-α, validating our methodology. In addition to these biological findings, development of the iTRAQ technique in combination with evaluation in knockout mouse lines will be important for identifying protein--protein interaction without prior knowledge of the complex and for identifying interactions that cannot be detected using traditional protein identification techniques. Identification of an nAChR-associated proteome also provides a set of novel targets for drug discovery of therapeutics for smoking cessation and psychiatric or neurological disorders associated with nicotinic dysfunction. Ultimately, generation of small molecules that are capable of disrupting or facilitating interactions between nAChRs and specific associated proteins holds the promise of providing more targeted therapies with higher selectivity for particular nAChR-mediated behavioral functions and fewer side effects.

Materials and methods {#s0045}
=====================

Chemicals {#s0050}
---------

Unless stated otherwise, all reagents were obtained from Sigma Aldrich (St. Louis, MO). \[^3^H\]-epibatidine (62.2 Ci/mmol) was purchased from PerkinElmer, Sheldon, CT. iTRAQ reagents were obtained from AB Sciex (Framingham, MA).

Animals {#s0055}
-------

Homozygous wild type (WT), heterozygous (HET) and homozygous (KO) mice lacking either α4 or β2 nAChR subunit were used in the study. β2 nAChR subunit [@b0020] and α4 nAChR subunit [@b0125] knockout (KO) mice were backcrossed at least 30 generations to a C57 BL/6 background. Mice were bred at the University of Colorado, Boulder, housed in groups of no more than 5 individuals per cage, maintained on a 12:12 h light:dark cycle and given *ad libitum* access to food and water. All protocols involving animals were approved by the Institutional Animal Care and Use Committee (IACUC) of Yale University and the University of Colorado and conformed to the standards for animal care and use set by the National Institutes of Health.

Preparation of brain tissue extracts for immunoprecipitation {#s0060}
------------------------------------------------------------

Animals were sacrificed by cervical dislocation and brains were rapidly placed on an ice-cold surface. After rinsed in chilled phosphate buffer solution (PBS, pH 7.4; containing 136.9 mM NaCl, 2.68 mM KCl, 10.14 mM Na~2~HPO~4~ and 1.76 mM KH~2~PO~4~) to carefully wash off any debris, brains were then snap frozen by immersion in −35 °C isopentane and kept frozen at −80 °C until use. On the day of tissue preparation, brains were thawed on a chilled surface and cerebellum was removed and discarded. The resulting tissue (whole forebrain) was homogenized by hand with 37 strokes in a glass tissue grinder in 10 volumes of extraction buffer (EB) (0.6% Triton X-100, 121.9 mM NaCl, 2.68 mM KCl, 10.14 mM Na~2~HPO~4~, 1.76 mM KH~2~PO~4~, 5 mM EDTA, 5 mM EGTA, 5 mM NaF, 0.1 mM Na~3~VO~4~, 1.0 mM PMSF and 10 μg/ml each of aprotonin, prepstatin A and leupeptin; pH 7.4). The resulting homogenate was incubated at 23 °C with gentle rotation for 30 min to facilitate protein solubilization, then subjected to centrifugation for 20 min at 5000 *g*, 4 °C. The resulting supernatant was used for all subsequent experiments.

\[^3^H\]-Epibatidine binding from mouse brain extracts {#s0065}
------------------------------------------------------

Measurement of the amount of high-affinity nAChRs in brain extracts was performed essentially as described previously [@b0260], except that 1 nM \[^3^H\]-epibatidine was used as the radioligand instead of 200 pM \[^125^I\]-epibatidine. \[^3^H\]-epibatidine labeled nAChRs were captured by filtration through a Packard Filtermate 196 Cell Harvester (Meriden, CT) onto Pall type A/D filters pre-soaked in 0.5% polyethylinimine. After washing three times with ice-cold wash buffer (140 mM NaCl, 1.5 mM KCl, 2.0 mM CaCl~2~, 1.0 mM MgSO~4~^.^7H2O, 25 mM HEPES, pH 7.5), radioactivity on individual filters was measured by liquid scintillation counting on a Beckmann LS6000LL (Indianapolis, IN) at 55% efficiency.

Immunoprecipitation {#s0070}
-------------------

mAb295 has been previously characterized as an antibody specific to β2^∗^ nAChRs [@b0005]. A solid phase mAb295 immunopurification matrix was prepared using M270 Dynabeads (Invitrogen) according to the manufacturer's instructions and stored in PBS containing 0.5% Triton X-100 and 0.02% NaN~3~ at 4 °C until use. On the day of IP, bead suspensions were aliquoted, separated on a magnetic stand, and rinsed once with PBS prior to the addition of brain supernatant. IP took place overnight at 4 °C with gentle rotation. Following IP, beads were separated with a magnetic stand and the supernatant was aspirated and discarded. Beads were then rinsed twice with PBS containing 0.01% Tween-20, then again in PBS only. Proteins were eluted from rinsed beads with 500 μl elution buffer (0.5 M NH~4~OH and 0.5 mM EDTA) by incubation at 23 °C for 20 min with gentle rotation. Elution was repeated one more time. The resulting eluate was then combined and lyophilized in a Speedvac DNA120 overnight. The lyophilized proteins were used for subsequent proteomic analysis.

iTRAQ labeling and protein identification by LC--MS/MS {#s0075}
------------------------------------------------------

All samples were prepared for iTRAQ analysis using a CHCl~3~/MeOH precipitation after diluting each to 100 μl with water. 400 μl of MeoH was then added and vortexed extensively prior to the addition of 100 μl CHCl~3~. An additional 300 μl of water was added prior to vortexing and centrifuging at 14,000*g* for 1 min. The top aqueous layer was removed and discarded and an additional 400 μl MeOH was added. After a 2 min centrifugation at 14,000 *g*, the MeOH was removed without disturbing the pellet. The pellet was dried in a Speedvac and dissolved in 50 μl of 0.5 M tetraethylammonium bicarbonate (TEAB) with 0.2% SDS. [Table S3](#s0110){ref-type="sec"} lists the amount of each sample used per sample set for labeling which was determined based on a nanodrop measurement at A~280~versus a buffer blank. Disulfide reduction was performed by incubating with 5 mM tris(2-carboxyethyl)phosphine (TCEP) at 60 °C for 1 h. Alkylation was then performed by incubating with 20 mM methylmethanethiolsulfonate (MMTS) at room temperature for 10 min. Samples were digested using a 1:10 weight/weight ratio protein/trypsin and incubating at 37 °C for 16 h. Each dried iTRAQ label was dissolved in 50 μl of 100% isopropanol. Reporter ion tags and sample identifications are listed in [Table S3](#s0110){ref-type="sec"}. After vortexing, each reconstituted iTRAQ reagent was transferred to the appropriate vial and incubated at room temperature for 2 h. At this point, the tagged sample digests were mixed together in each indicated set. 100 μg of sample mixture was then passed over a cation exchange cartridge (AB Sciex) to remove unreacted reagent. The sample was diluted with 2 mL of 10 mM KH~2~PO~4~/25% acetonitrile (ACN) (pH 3.0) prior to passing over the cation exchange cartridge (conditioned with 10 mM KH~2~PO~4~/ 25% ACN, pH 3.0). The cartridge was then washed with 1 mL of the same buffer prior to eluting the peptides with 500 μl 10 mM KH~2~PO~4~, 25% ACN, 350 mM KCl (pH 3.0). The samples were dried, dissolved in 20 μl 70% formic acid (FA) and diluted with 300 μl 0.1% trifluoroacetic acid (TFA), prior to desalting using a Macrospin C18 (The Nest Group, \# SMM SS18V). The bound peptides were eluted with 360 μl of 80% ACN containing 0.1% TFA and the elution was repeated by washing with an additional 180 μl of same solution. Samples were dried in a Speedvac and dissolved in 3 μl FA mixed with 8 μl 0.1% TFA.

Mass spectrometric analysis was performed on an AB Sciex TripleTOF 5600 which is equipped with a Waters nanoAcquity UPLC system, and uses a Waters Symmetry C18 180 μm × 20 mm trap column and a 1.7 μm, 75 μm × 150 mm nanoAcquity UPLC column (45 °C) for peptide separation with the following multiplexed groups: *Set 1 with 6 plex* containing α4WT1, α4HET1, α4KO1, β2WT1, β2HET1 and β2KO1; *Set 2 with 6 plex* containing α4WT2, α4HET2, α4KO2, β2WT2, β2HET2 and β2KO2, and *Set 3 with 6 plex* containing α4WT3, α4HET3, α4KO3, β2WT3, β2HET3 and β2KO3.

Trapping was done at 15 μl/min, 99% Buffer A (99.9% water and 0.1% FA) for 1 min. Peptide separation was performed at 500 nl/min with Buffer A and Buffer B (99.925% and 0.075% FA). The gradient was 99% A at initial conditions with a linear gradient to 35% B at 160 min, and 95% B at 160.3 min. Protein identification and iTRAQ quantitation was performed using AB SCIEX ProteinPilot ver 4.2, which employs a Paragon algorithm with hybrid sequence tag and feature probability database searches [@b0265]. Hence, specific details such as mass tolerances, specific modifications, *etc*. are not used. All iTRAQ results were uploaded into the Yale protein expression database (YPED; <http://yped.med.yale.edu/repository/>) [@b0270].

Data analysis {#s0080}
-------------

### Ligand binding and immunoprecipitation {#s0085}

Ligand binding results were transformed from counts per minute (CPM) to fmol of bound ligand for all quantitations. To determine the maximally effective ratio of mAb bead volume for quantitative immunoprecipitation, the average depletion of nicotinic binding sites relative to the input was calculated using a 3-component hyperbolic equation *y* = *y*~0~ + *a*(*x*)/\[*b* + (*x*)\], where "*y*" is bound ligand captured with residual binding "*y*~0~", maximal depletion "*a*" at ½ maximal \[bead\] "*b*" and \[mAb\] "*x*". Curve fits were performed with the abovementioned equation in SigmaPlot 2001. Statistical significance of the influence of genotype and/or antibody capture efficiency was determined by Student's *t*-test or a one-way ANOVA (when comparing two or more groups, respectively) conducted with SPSS19 with a confidence interval set at 95%.

### iTRAQ data analysis {#s0090}

For relative quantitation of proteins identified by LC--MS/MS, the quantified proteins should have a confidence interval for positive identification greater than 95% with at least two unique peptides contributing to the identification. The reporter ion peak areas for each peptide measured were averaged for each protein identified in every group to provide an MRIPA. A control mean for every identified protein was generated by averaging the MRIPA for the two nAChR wild type control animals (α4WT and β2WT). All samples within a set were divided by these control means in order to calculate the ratios of MRIPA in relative to an averaged control set. The ratio of each identified protein to the level of nAChR proteins was then log~2~ transformed and used to measure the relative quantitative expression. Except where indicated, log~2~MRIPA was used in all statistical analyses of iTRAQ data within this study. For regression analysis across biological replicates, log~2~MRIPA of each protein was correlated with that of the β2 nAChR subunit. Regression and correlation analysis was conducted using SPSS 19 with a confidence interval set at 95%. The frequency distribution of identified proteins was interrogated using the Shapiro--Wilk test of normality with a confidence interval set at 95%.
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Supplementary Figure 1Optimization of β2∗ nAChR immunopurification (A) Titration of immunopurification. Depletion of high affinity \[^3^H\]-epibatidine binding sites from whole mouse brain detergent extracts with immobilized mAb295 on M270 Dynabeads at 0.5 μg/mg (red circles), 1.0 μg/mg (green circles), 2.0 μg/mg (red triangles), and 5.0 μg/mg (orange triangles) is saturable and nearly quantitative. (B) Relationship of \[mAb\]: capture efficiency. The required bead volume to achieve ½-maximal depletion decreases with increasing concentration of mAb295, indicating that total mAb295 content is more critical for efficient IP than total bead surface areaSupplementary Table 1**Calculated parameters for efficient and specific capture of β2^∗^ nAChRs from mouse brain detergent extracts**.Supplementary Table 2**Proteins identified by iTRAQ following immunopurification of β2^∗^ nAChRs from mouse brain detergent extracts**.Supplementary Table 3**Details of iTRAQ label tags by sample**.
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![**Gene dose-dependent effects of nAChR subunit gene deletion on the relative protein abundance of α4 and β2 subunits** The relative abundance of α4 and β2 nAChR subunits determined by iTRAQ quantitation of the log~2~ mean reporter ion peak areas (log~2~MRIPA) is significantly altered as measured by an overall ANOVA by the full or partial gene deletion of either subunit (α4: *n* = 9, *F*~(2,~ ~8)~ = 7.39, *P* = 0.024; β2: *n* = 9, *F*~(2,~ ~8)~ = 8.35, *P* = 0.018). Gene dose-dependent decreases in abundance demonstrate the interdependence of α4 and β2 nAChR subunits in mouse brain. MRIPA stands for mean reporter ion peak area.](gr1){#f0005}

![**Correlation of nAChR abundance measured by iTRAQ and ligand binding** Correlation between fmol of \[^3^H\]-epibatidine binding and measured log~2~MRIPA of α4 and β2 was plotted. The relative abundance of α4 (black circles) and β2 (white circles) nAChR subunits measured by iTRAQ follow a gene-dose dependent decrease and is significantly correlated with \[^3^H\]-epibatidine binding across the six genotypes examined (WT, HET and KO; α4: *r* = 0.894, *P \< *0.0009; β2: *r* = 0.804, *P \< *0.0009).](gr2){#f0010}

![**Frequency distribution of correlations for proteins associated with β2 subunit** Frequency distribution of calculated correlations between relative abundances of putative interacting proteins and β2 nAChR log~2~RIPA was shown. **A.** The primary dataset (no protein exclusion) is bimodal, indicating the presence of a substantial number of proteins identified with no significant correlation or a negative correlation. **B.** The major (negative correlation) mode is lost when identified proteins in cellular compartments that do not normally contain nAChRs are removed (secondary dataset), resulting in a skewed distribution. **C.** The tertiary dataset (significantly correlated proteins) is also predictably skewed, indicating that the edited dataset favors proteins that are enriched for the β2 nAChR subunit.](gr3){#f0015}

###### 

**Gene dose-dependent effect on the number of \[**^**3**^**H\]-epibatidine binding sites of nAChRs**

  Number of \[^3^H\]-epibatidine binding sites (fmol)   Genotype        *F*~(2,~ ~8)~ score   *P* value                             
  ----------------------------------------------------- --------------- --------------------- --------------- ------------- ------- -------
  Total in brain extracts (mean ± SEM)                  α4              609.3 ± 101.5         514.0 ± 109.0   51.9 ± 4.5    12.00   0.008
  β2                                                    633.6 ± 124.0   463.6 ± 2.6           38.9 ± 9.7      18.17         0.003   
                                                                                                                                    
  Captured by immobilized mAb295 (mean ± SEM)           α4              522.7 ± 120.3         420.3 ± 116.8   −1.0 ± 12.2   8.18    0.019
  β2                                                    505.6 ± 103.5   365.2 ± 6.5           −5.0 ± 10.5     19.21         0.002   

###### 

**Proteins specifically associated with nAChRs based on cellular compartments**.

  Correlation coefficient   *N*   *F* score   *P* value   Protein                                                            UniProtKB accession No.               Cellular compartment                Previously identified?
  ------------------------- ----- ----------- ----------- ------------------------------------------------------------------ ------------------------------------- ----------------------------------- ------------------------
  0.185                     18    0.568       0.462       14-3-3 protein ζ/δ                                                 [P63101](uniprotkb:P63101){#ir0015}   Cytoplasm                           Yes
  0.117                     18    0.221       0.645       2′,3′-cyclic-nucleotide 3′-phosp hodiesterase                      [P16330](uniprotkb:P16330){#ir0020}   Cell membrane                       Yes
  0.326                     18    1.909       0.186       Actin, alpha cardiac muscle 1                                      [P68033](uniprotkb:P68033){#ir0025}   Cytoplasm                           No
  0.375                     18    2.623       0.125       Actin, cytoplasmic 2                                               [P63260](uniprotkb:P63260){#ir0030}   Cytoplasm                           Yes
  0.645                     18    11.404      0.004       Actin-related protein 3                                            [Q99JY9](uniprotkb:Q99JY9){#ir0035}   Cytoplasm                           No
  0.37                      18    2.536       0.131       α-actinin-1                                                        [Q7TPR4](uniprotkb:Q7TPR4){#ir0040}   Cytoplasm                           No
  0.104                     12    0.11        0.747       α-actinin-2                                                        [Q9JI91](uniprotkb:Q9JI91){#ir0045}   Cytoplasm                           No
  0.162                     12    0.271       0.614       α-enolase                                                          [P17182](uniprotkb:P17182){#ir0050}   Cytoplasm                           No
  0.464                     18    4.4         0.052       α-internexin                                                       [P46660](uniprotkb:P46660){#ir0055}   Cytoplasm                           No
  0.227                     18    0.866       0.366       Ankyrin-2                                                          [Q8C8R3](uniprotkb:Q8C8R3){#ir0060}   Cytoplasm                           No
  0.021                     12    0.005       0.948       Brain acid soluble protein 1                                       [Q91XV3](uniprotkb:Q91XV3){#ir0065}   Cell membrane                       No
  0.637                     18    10.904      0.004       Calcium/calmodulin-dependent protein kinase type II subunit α      [P11798](uniprotkb:P11798){#ir0070}   Cytoplasm                           No
  0.172                     6     0.49        0.494       Calcium/calmodulin-dependent protein kinase type II subunit β      [P28652](uniprotkb:P28652){#ir0075}   Cytoplasm                           No
  0.456                     6     1.048       0.364       Calcium/calmodulin-dependent protein kinase type II subunit δ      [Q6PHZ2](uniprotkb:Q6PHZ2){#ir0080}   Cell membrane                       No
  0.917                     18    21.235      0.01        Calcium/calmodulin-dependent protein kinase type II subunit γ      [Q923T9](uniprotkb:Q923T9){#ir0085}   Sarcoplasmic reticulum membrane     No
  0.235                     18    0.938       0.347       Coronin-2B                                                         [Q8BH44](uniprotkb:Q8BH44){#ir0090}   Cytoplasm                           No
  0.598                     6     2.221       0.21        Dihydropyrimidinase-related protein 2                              [O08553](uniprotkb:O08553){#ir0095}   Cytoplasm                           No
  0.186                     18    0.143       0.724       Disks large homolog 4                                              [Q62108](uniprotkb:Q62108){#ir0100}   Cell membrane                       Yes
  0.468                     18    4.495       0.05        Drebrin                                                            [Q9QXS6](uniprotkb:Q9QXS6){#ir0105}   Cytoplasm                           No
  0.327                     18    1.911       0.186       Dynein light chain 2, cytoplasmic                                  [Q9D0M5](uniprotkb:Q9D0M5){#ir0110}   Cytoplasm                           No
  0.539                     18    6.563       0.021       Ectonucleotide pyrophosphatase/phosphodiesterase family member 6   [Q8BGN3](uniprotkb:Q8BGN3){#ir0115}   Cell membrane                       No
  0.386                     6     2.807       0.113       EF-hand domain-containing protein D2                               [Q9D8Y0](uniprotkb:Q9D8Y0){#ir0120}   Membrane raft                       No
  0.57                      18    7.681       0.014       F-actin-capping protein subunit α2                                 [P47754](uniprotkb:P47754){#ir0125}   Cytoplasm                           No
  0.46                      6     4.286       0.055       F-actin-capping protein subunit β                                  [P47757](uniprotkb:P47757){#ir0130}   Cytoplasm                           No
  0.337                     18    2.052       0.171       Gelsolin                                                           [P13020](uniprotkb:P13020){#ir0135}   Cytoplasm                           No
  0.748                     12    20.268      0           Glial fibrillary acidic protein                                    [P03995](uniprotkb:P03995){#ir0140}   Cytoplasm                           No
  0.476                     18    2.937       0.117       Glutamine synthetase                                               [P15105](uniprotkb:P15105){#ir0145}   Cytoplasm                           No
  0.417                     18    3.371       0.085       Glyceraldehyde-3-phosphate dehydrogenase                           [P16858](uniprotkb:P16858){#ir0150}   Cytoplasm                           Yes
  0.045                     18    0.033       0.859       Guanine nucleotide-binding protein G(o) subunit α                  [P18872](uniprotkb:P18872){#ir0155}   Heterotrimeric G-protein complex    Yes
  0.193                     18    0.622       0.442       Heat shock cognate 71 kDa protein                                  [P63017](uniprotkb:P63017){#ir0160}   Cytoplasm                           No
  0.46                      18    4.29        0.055       Heterogeneous nuclear ribonucleoprotein D0                         [Q60668](uniprotkb:Q60668){#ir0165}   Nucleus                             No
  0.486                     12    1.237       0.328       Heterogeneous nuclear ribonucleoprotein U                          [Q8VEK3](uniprotkb:Q8VEK3){#ir0170}   Nucleus                             No
  0.243                     6     1.957       0.192       [l]{.smallcaps}-Lactate dehydrogenase A chain                      [P16125](uniprotkb:P16125){#ir0175}   Cytoplasm                           No
  0.332                     18    1.984       0.178       Myelin basic protein                                               [P04370](uniprotkb:P04370){#ir0180}   Myelin membrane                     Yes
  0.332                     18    1.984       0.178       Myelin basic protein                                               [P04370](uniprotkb:P04370){#ir0185}   Myelin membrane                     Yes
  0.506                     18    5.496       0.032       Myelin proteolipid protein                                         [P60202](uniprotkb:P60202){#ir0190}   Cell membrane                       No
  0.262                     18    1.183       0.293       Myosin light polypeptide 6                                         [Q60605](uniprotkb:Q60605){#ir0195}   Cytoplasm                           No
  0.512                     18    5.695       0.03        Myosin-10                                                          [Q61879](uniprotkb:Q61879){#ir0200}   Cytoplasm                           No
  0.085                     18    0.117       0.737       Myosin-9                                                           [Q8VDD5](uniprotkb:Q8VDD5){#ir0205}   Cytoplasm                           No
  0.652                     18    11.844      0.003       Neurofilament light polypeptide                                    [P08551](uniprotkb:P08551){#ir0210}   Growth cone                         No
  0.379                     18    2.683       0.121       Neurofilament medium polypeptide                                   [P08553](uniprotkb:P08553){#ir0215}   Growth cone                         No
  0.858                     18    44.542      0           Neuronal acetylcholine receptor subunit α4                         [O70174](uniprotkb:O70174){#ir0220}   Cell junction                       No
  1                         18    --          0           Neuronal acetylcholine receptor subunit β2                         [Q9ERK7](uniprotkb:Q9ERK7){#ir0225}   Cell junction                       No
  0.02                      18    0.006       0.938       Peptidyl-prolyl *cis*--*trans* isomerase A                         [P17742](uniprotkb:P17742){#ir0230}   Cytoplasm                           No
  0.431                     6     2.279       0.162       Peroxiredoxin-1                                                    [P35700](uniprotkb:P35700){#ir0235}   Cytoplasm                           No
  0.484                     12    3.061       0.111       Pyruvate kinase isozymes M1/M2                                     [P52480](uniprotkb:P52480){#ir0240}   Cytoplasm                           No
  0.287                     12    0.901       0.365       Ras-related protein Rab-11B                                        [P46638](uniprotkb:P46638){#ir0245}   Cell membrane                       No
  0.397                     6     1.867       0.202       Ras-related protein Rab-7a                                         [P51150](uniprotkb:P51150){#ir0250}   Late endosome                       No
  0.31                      12    1.063       0.327       Ras-related protein Ral-A                                          [P63321](uniprotkb:P63321){#ir0255}   Cell membrane                       No
  0.856                     6     11.009      0.029       Ras-related protein Rap-1A                                         [P62835](uniprotkb:P62835){#ir0260}   Cell membrane                       No
  0.171                     6     0.302       0.595       Ras-related protein Rap-1b                                         [Q99JI6](uniprotkb:Q99JI6){#ir0265}   Cell membrane                       No
  0.443                     12    2.44        0.149       Serine/threonine-protein phosphatase PP1β catalytic subunit        [P62141](uniprotkb:P62141){#ir0270}   Cytoplasm                           No
  0.69                      6     3.633       0.129       Serine/threonine-protein phosphatase PP1γ catalytic subunit        [P63087](uniprotkb:P63087){#ir0275}   Cytoplasm                           No
  0.224                     12    0.529       0.484       Sodium/potassium-transporting ATPase subunit α2                    [Q6PIE5](uniprotkb:Q6PIE5){#ir0280}   Cell membrane                       No
  0.261                     18    1.169       0.296       Sodium/potassium-transporting ATPase subunit α3                    [Q6PIC6](uniprotkb:Q6PIC6){#ir0285}   Cell membrane                       No
  0.266                     18    1.217       0.286       Sodium/potassium-transporting ATPase subunit β1                    [P14094](uniprotkb:P14094){#ir0290}   Cell membrane                       No
  0.502                     18    5.378       0.034       Spectrin α chain, brain                                            [P16546](uniprotkb:P16546){#ir0295}   Cytoplasm                           Yes
  0.519                     18    5.884       0.027       Spectrin β chain, brain 1                                          [Q62261](uniprotkb:Q62261){#ir0300}   Cytoplasm                           No
  0.299                     18    1.566       0.229       Synaptopodin                                                       [Q8CC35](uniprotkb:Q8CC35){#ir0305}   Cytoplasm                           No
  0.547                     12    4.265       0.066       Synaptotagmin-1                                                    [P46096](uniprotkb:P46096){#ir0310}   Cytoplasmic vesicle                 No
  0.536                     12    4.026       0.073       Syntaxin-1B                                                        [P61264](uniprotkb:P61264){#ir0315}   Cell membrane                       No
  0.086                     18    0.119       0.734       Syntaxin-binding protein 1                                         [O08599](uniprotkb:O08599){#ir0320}   Cell membrane                       No
  0.562                     18    7.386       0.015       Thyroid hormone receptor-associated protein 3                      [Q569Z6](uniprotkb:Q569Z6){#ir0325}   Nucleus                             No
  0.665                     12    7.933       0.018       Transcriptional activator protein Pur-α                            [P42669](uniprotkb:P42669){#ir0330}   Nucleus                             No
  0.491                     6     1.272       0.322       Triosephosphate isomerase                                          [P17751](uniprotkb:P17751){#ir0335}   Cytoplasm                           No
  0.334                     18    2.011       0.175       Tropomodulin-2                                                     [Q9JKK7](uniprotkb:Q9JKK7){#ir0340}   Cytoplasm                           No
  0.451                     18    4.087       0.06        Tubulin α-1A chain                                                 [P68369](uniprotkb:P68369){#ir0345}   Cytoplasm                           Yes
  0.431                     18    3.652       0.074       Tubulin α-4A chain                                                 [P68368](uniprotkb:P68368){#ir0350}   Cytoplasm                           No
  0.422                     18    3.466       0.081       Tubulin β-2A chain                                                 Q7TM M 9                              Cytoplasm                           No
  0.493                     18    5.149       0.037       Tubulin β-3 chain                                                  [Q9ERD7](uniprotkb:Q9ERD7){#ir0355}   Cytoplasm                           No
  0.379                     18    2.688       0.121       Tubulin β-4A chain                                                 [Q9D6F9](uniprotkb:Q9D6F9){#ir0360}   Cytoplasm                           No
  0.432                     12    2.298       0.16        Tubulin β-5 chain                                                  [P99024](uniprotkb:P99024){#ir0365}   Cytoplasm                           No
  0.434                     18    3.717       0.072       Unconventional myosin-Va                                           [Q99104](uniprotkb:Q99104){#ir0370}   Cytoplasm                           No
  0.295                     18    1.52        0.235       Unconventional myosin-VI                                           [Q64331](uniprotkb:Q64331){#ir0375}   Golgi apparatus                     No
  0.01                      12    0.001       0.975       Unconventional myosin-XVIIIa                                       [Q9JMH9](uniprotkb:Q9JMH9){#ir0380}   ER-Golgi intermediate compartment   No
  0.18                      6     0.537       0.474       Vesicle-fusing ATPase                                              [P46460](uniprotkb:P46460){#ir0385}   Cytoplasm                           No
  0.195                     18    0.158       0.712       Vimentin                                                           [P20152](uniprotkb:P20152){#ir0390}   Cytoplasm                           No
  0.179                     6     0.527       0.478       V-type proton ATPase catalytic subunit A                           [P50516](uniprotkb:P50516){#ir0395}   Cell membrane                       No

*Note:* Correlation coefficient was calculated using Pearson's product moment; *N* indicates the number of samples contributing to analysis; *F* score was generated by one-way ANOVA.

###### 

**Proteins with their abundances significantly positively correlated with that of β2 nAChR subunit across genotypes**.

  Correlation coefficient   *N*   *F* score   *P* value   Protein                                                            UniProtKB accession No.               Cellular compartment              Previously identified?   Molecular function
  ------------------------- ----- ----------- ----------- ------------------------------------------------------------------ ------------------------------------- --------------------------------- ------------------------ -------------------------------------------------------------------------------
  0.748                     12    20.268      0           Glial fibrillary acidic protein                                    [P03995](uniprotkb:P03995){#ir0400}   Cytoplasm                         No                       Protein binding, structural molecule
  0.858                     18    44.542      0           nAChR subunit α4                                                   [O70174](uniprotkb:O70174){#ir0405}   Cell junction                     No                       Neuro-transmitter receptor
  1                         18    --          0           nAChR subunit β2                                                   [Q9ERK7](uniprotkb:Q9ERK7){#ir0410}   Cell junction                     No                       Neuro-transmitter receptor
  0.652                     18    11.844      0.003       Neurofilament light poly peptide                                   [P08551](uniprotkb:P08551){#ir0415}   Growth cone                       No                       Protein binding, structural molecule
  0.645                     18    11.404      0.004       Actin-related protein 3                                            [Q99JY9](uniprotkb:Q99JY9){#ir0420}   Cytoplasm                         No                       Nucleotide binding, protein binding
  0.637                     18    10.904      0.004       Calcium/calmodulin-dependent protein kinase type II subunit α      [P11798](uniprotkb:P11798){#ir0425}   Cytoplasm                         No                       Transferase, nucleotide binding, protein binding
  0.917                     18    21.235      0.01        Calcium/calmodulin-dependent protein kinase type II subunit γ      [Q923T9](uniprotkb:Q923T9){#ir0430}   Sarcoplasmic reticulum membrane   No                       Transferase, nucleotide binding, protein binding
  0.57                      18    7.681       0.014       F-actin-capping protein subunit α2                                 [P47754](uniprotkb:P47754){#ir0435}   Cytoplasm                         No                       Protein binding
  0.562                     18    7.386       0.015       Thyroid hormone receptor- associated protein 3                     [Q569Z6](uniprotkb:Q569Z6){#ir0440}   Nucleus                           No                       Nucleotide binding, protein binding
  0.665                     12    7.933       0.018       Transcriptional activator protein Pur-α                            [P42669](uniprotkb:P42669){#ir0445}   Nucleus                           No                       Nucleic acid binding, translation regulator, protein binding
  0.539                     18    6.563       0.021       Ectonucleotide pyrophosphatase/phosphodiesterase family member 6   [Q8BGN3](uniprotkb:Q8BGN3){#ir0450}   Cell membrane                     No                       Catalytic activity, hydrolase activity
  0.519                     18    5.884       0.027       Spectrin β chain, brain 1                                          [Q62261](uniprotkb:Q62261){#ir0455}   Cytoplasm                         No                       Protein binding, lipid binding, structural molecule activity
  0.856                     6     11.009      0.029       Ras-related protein Rap-1A                                         [P62835](uniprotkb:P62835){#ir0460}   Cell membrane                     No                       Hydrolase activity, protein binding, nucleotide binding
  0.512                     18    5.695       0.03        Myosin-10                                                          [Q61879](uniprotkb:Q61879){#ir0465}   Cytoplasm                         No                       Protein binding, nucleotide binding, hydrolase
  0.506                     18    5.496       0.032       Myelin proteolipid protein                                         [P60202](uniprotkb:P60202){#ir0470}   Cell membrane                     No                       Structural molecular, protein binding
  0.502                     18    5.378       0.034       Spectrin α chain, brain                                            [P16546](uniprotkb:P16546){#ir0475}   Cytoplasm                         Yes                      Hydrolase, protein binding, nucleotide binding
  0.493                     18    5.149       0.037       Tubulin β-3 chain                                                  [Q9ERD7](uniprotkb:Q9ERD7){#ir0480}   Cytoplasm                         No                       Hydrolase, nucleotide binding, structural molecular, protein binding, peptide
